Amgen Inc. (AMGN)

$266.81

-0.89

(-0.33%)▲

Live

star icon

Amgen, Inc. is a biopharmaceutical company that is involved in the development and commercialization of drugs for various diseases.

Insights on Amgen Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 6.10B → 6.98B (in $), with an average increase of 12.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.84B → 1.37B (in $), with an average decrease of 51.5% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 76.8% return, outperforming this stock by 58.9%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 266.4% return, outperforming this stock by 256.6%

Performance

  • $265.11
    $267.35
    $266.81
    downward going graph

    0.64%

    Downside

    Day's Volatility :0.84%

    Upside

    0.2%

    downward going graph
  • $210.01
    $287.01
    $266.81
    downward going graph

    21.29%

    Downside

    52 Weeks Volatility :26.83%

    Upside

    7.04%

    downward going graph

Returns

PeriodAmgen Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
19.12%
-1.4%
-2.1%
6 Months
13.07%
2.2%
11.7%
1 Year
18.0%
6.0%
21.6%
3 Years
9.79%
26.3%
21.1%

Highlights

Market Capitalization
143.2B
Book Value
$12.68
Dividend Share
8.14
Dividend Yield
3.14%
Earnings Per Share (EPS)
14.85
PE Ratio
18.03
PEG Ratio
1.55
Wall Street Target Price
263.68
Profit Margin
30.02%
Operating Margin TTM
38.44%
Return On Assets TTM
8.54%
Return On Equity TTM
173.46%
Revenue TTM
26.6B
Revenue Per Share TTM
49.73
Quarterly Revenue Growth YOY
5.8999999999999995%
Gross Profit TTM
19.9B
EBITDA
13.8B
Diluted Eps TTM
14.85
Quarterly Earnings Growth YOY
0.05
EPS Estimate Current Year
18.3
EPS Estimate Next Year
19.01
EPS Estimate Current Quarter
4.49
EPS Estimate Next Quarter
4.62

Analyst Recommendation

Buy
    45%Buy
    42%Hold
    12%Sell
Based on 33 Wall street analysts offering stock ratings for Amgen Inc.(by analysts ranked 0 to 5 stars)
Based on 33 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
14
14
14
Sell
4
4
4

Analyst Forecast

What analysts predicted

Downside of 1.17%

Current $266.81
Target $263.68

Company Financials

FY17Y/Y Change
Revenue
22.8B
↓ 0.62%
Net Income
2.0B
↓ 74.37%
Net Profit Margin
8.66%
↓ 24.93%
FY18Y/Y Change
Revenue
23.7B
↑ 3.93%
Net Income
8.4B
↑ 324.15%
Net Profit Margin
35.35%
↑ 26.69%
FY19Y/Y Change
Revenue
23.4B
↓ 1.62%
Net Income
7.8B
↓ 6.58%
Net Profit Margin
33.57%
↓ 1.78%
FY20Y/Y Change
Revenue
25.4B
↑ 8.83%
Net Income
7.3B
↓ 7.37%
Net Profit Margin
28.57%
↓ 5.0%
FY21Y/Y Change
Revenue
26.0B
↑ 2.18%
Net Income
5.9B
↓ 18.87%
Net Profit Margin
22.68%
↓ 5.89%
FY22Y/Y Change
Revenue
26.3B
↑ 1.32%
Net Income
6.6B
↑ 11.18%
Net Profit Margin
24.89%
↑ 2.21%
Q1 FY22Q/Q Change
Revenue
6.2B
↓ 8.88%
Net Income
1.5B
↓ 22.27%
Net Profit Margin
23.66%
↓ 4.08%
Q2 FY22Q/Q Change
Revenue
6.6B
↑ 5.71%
Net Income
1.3B
↓ 10.77%
Net Profit Margin
19.97%
↓ 3.69%
Q3 FY22Q/Q Change
Revenue
6.7B
↑ 0.88%
Net Income
2.1B
↑ 62.72%
Net Profit Margin
32.22%
↑ 12.25%
Q4 FY22Q/Q Change
Revenue
6.8B
↑ 2.81%
Net Income
1.6B
↓ 24.59%
Net Profit Margin
23.63%
↓ 8.59%
Q1 FY23Q/Q Change
Revenue
6.1B
↓ 10.73%
Net Income
2.8B
↑ 75.8%
Net Profit Margin
46.54%
↑ 22.91%
Q2 FY23Q/Q Change
Revenue
7.0B
↑ 14.43%
Net Income
1.4B
↓ 51.46%
Net Profit Margin
19.74%
↓ 26.8%
FY17Y/Y Change
Total Assets
80.0B
↑ 3.0%
Total Liabilities
54.7B
↑ 14.58%
FY18Y/Y Change
Total Assets
66.4B
↓ 16.93%
Total Liabilities
53.9B
↓ 1.46%
FY19Y/Y Change
Total Assets
59.7B
↓ 10.1%
Total Liabilities
50.0B
↓ 7.2%
FY20Y/Y Change
Total Assets
62.9B
↑ 5.43%
Total Liabilities
53.5B
↑ 7.01%
FY21Y/Y Change
Total Assets
61.2B
↓ 2.83%
Total Liabilities
54.5B
↑ 1.73%
FY22Y/Y Change
Total Assets
65.1B
↑ 6.47%
Total Liabilities
61.5B
↑ 12.84%
Q1 FY22Q/Q Change
Total Assets
59.2B
↓ 3.22%
Total Liabilities
58.3B
↑ 7.0%
Q2 FY22Q/Q Change
Total Assets
59.3B
↑ 0.17%
Total Liabilities
56.9B
↓ 2.41%
Q3 FY22Q/Q Change
Total Assets
63.7B
↑ 7.43%
Total Liabilities
60.0B
↑ 5.58%
Q4 FY22Q/Q Change
Total Assets
65.1B
↑ 2.23%
Total Liabilities
61.5B
↑ 2.35%
Q1 FY23Q/Q Change
Total Assets
88.7B
↑ 36.24%
Total Liabilities
83.4B
↑ 35.65%
Q2 FY23Q/Q Change
Total Assets
90.3B
↑ 1.75%
Total Liabilities
83.5B
↑ 0.14%
FY17Y/Y Change
Operating Cash Flow
11.2B
↑ 7.95%
Investing Cash Flow
-4.0B
↓ 53.52%
Financing Cash Flow
-6.6B
↑ 153.71%
FY18Y/Y Change
Operating Cash Flow
11.3B
↑ 1.06%
Investing Cash Flow
14.3B
↓ 456.34%
Financing Cash Flow
-22.5B
↑ 241.07%
FY19Y/Y Change
Operating Cash Flow
9.2B
↓ 19.0%
Investing Cash Flow
5.7B
↓ 60.19%
Financing Cash Flow
-15.8B
↓ 29.89%
FY20Y/Y Change
Operating Cash Flow
10.5B
↑ 14.72%
Investing Cash Flow
-5.4B
↓ 194.61%
Financing Cash Flow
-4.9B
↓ 69.13%
FY21Y/Y Change
Operating Cash Flow
9.3B
↓ 11.77%
Investing Cash Flow
733.0M
↓ 113.57%
Financing Cash Flow
-8.3B
↑ 69.94%
Q1 FY22Q/Q Change
Operating Cash Flow
2.2B
↓ 22.93%
Investing Cash Flow
-111.0M
↓ 51.74%
Financing Cash Flow
-3.5B
↓ 46.42%
Q2 FY22Q/Q Change
Operating Cash Flow
1.9B
↓ 10.81%
Investing Cash Flow
-2.2B
↑ 1875.68%
Financing Cash Flow
-1.1B
↓ 69.78%
Q3 FY22Q/Q Change
Operating Cash Flow
3.0B
↑ 54.3%
Investing Cash Flow
-267.0M
↓ 87.82%
Financing Cash Flow
1.6B
↓ 249.53%
Q1 FY23Q/Q Change
Operating Cash Flow
1.1B
↓ 59.83%
Investing Cash Flow
1.4B
-
Financing Cash Flow
21.5B
↓ 2150.43%
Q2 FY23Q/Q Change
Operating Cash Flow
4.1B
↑ 286.18%
Investing Cash Flow
-211.0M
↓ 115.54%
Financing Cash Flow
-1.2B
↓ 105.63%

Technicals Summary

Sell

Neutral

Buy

Amgen Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amgen Inc.
Amgen Inc.
4.42%
13.07%
18.0%
9.79%
29.66%
Eli Lilly And Company
Eli Lilly And Company
-0.56%
64.54%
79.04%
266.39%
420.85%
Johnson & Johnson
Johnson & Johnson
-3.46%
4.7%
-3.14%
10.19%
15.77%
Merck & Co. Inc.
Merck & Co. Inc.
-3.51%
-0.55%
23.39%
28.23%
50.52%
Abbvie Inc.
Abbvie Inc.
4.12%
-3.05%
8.17%
77.13%
62.87%
Pfizer Inc.
Pfizer Inc.
-10.14%
-18.72%
-25.42%
-9.32%
-25.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amgen Inc.
Amgen Inc.
18.03
18.03
1.55
18.3
1.73
0.09
0.03
12.68
Eli Lilly And Company
Eli Lilly And Company
76.62
76.62
2.18
9.77
0.66
0.1
0.01
12.3
Johnson & Johnson
Johnson & Johnson
32.72
32.72
3.79
9.39
0.17
0.09
0.03
28.92
Merck & Co. Inc.
Merck & Co. Inc.
87.48
87.48
1.36
3.03
0.08
0.05
0.03
15.24
Abbvie Inc.
Abbvie Inc.
31.64
31.64
1.28
11.06
0.63
0.09
0.04
7.29
Pfizer Inc.
Pfizer Inc.
8.74
8.74
1.17
3.09
0.23
0.08
0.05
17.54
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amgen Inc.
Amgen Inc.
Buy
$143.2B
29.66%
18.03
30.02%
Eli Lilly And Company
Eli Lilly And Company
Buy
$522.2B
420.85%
76.62
22.01%
Johnson & Johnson
Johnson & Johnson
Hold
$389.3B
15.77%
32.72
13.35%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$270.8B
50.52%
87.48
5.34%
Abbvie Inc.
Abbvie Inc.
Buy
$270.8B
62.87%
31.64
15.5%
Pfizer Inc.
Pfizer Inc.
Hold
$185.5B
-25.35%
8.74
27.55%

Institutional Holdings

  • Vanguard Group Inc

    9.14%

  • BlackRock Inc

    8.78%

  • State Street Corporation

    5.44%

  • PRIMECAP Management Company

    2.76%

  • Morgan Stanley - Brokerage Accounts

    2.54%

  • Geode Capital Management, LLC

    2.21%

Corporate Announcements

  • Amgen Inc. Dividends March,2023

    In the quarter ending March,2023. Amgen Inc. has declared dividend of $2.13

    Read More

Company Information

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

Organization
Amgen Inc.
Employees
25200
CEO
Mr. Robert A. Bradway
Industry
Health Technology

Discover More

FAQs